MiMedx Group

MiMedx Group, Inc. is a therapeutic biologics company, which engages in the design, manufacture, and marketing of products, and tissue processing services. It serves the wound care, burn, surgical, orthopedic, spine, sports medicine, ophthalmic, and dental sectors of healthcare. Its biomaterial platform technologies include AmnioFix and EpiFix, a tissue allografts derived from amnion and chorion layers of human placental membrane, EpiCord and AmnioCord, a tissue allografts derived from umbilical cord tissue, and AmnioFill, a placental connective tissue matrix derived from the placental disc and other placental tissue. The company was founded on July 30, 1985 and is headquartered in Marietta, GA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

MiMedx Group reports robust Q4 performance and eyes growth opportunities

MiMedx Group's Q4 2022 earnings call highlighted strong performance, strategic focus on growth objectives, and addressing challenges in reimbursement and regulatory landscape. The company's emphasis on technology, personnel, and growth opportunities positions it for continued success.

MiMedx Group reports robust Q1 performance and eyes international growth

MiMedx Group's Q1 2023 performance reflects a balanced focus on profitability and revenue growth, driven by new product launches and strategic initiatives.
Despite challenges such as product launch delays and market dynamics, the company remains optimistic about growth opportunities in Japan and beyond.
With a strong emphasis on efficiency, innovation, and market expansion, MiMedx Group is positioned for continued growth and success in the evolving healthcare landscape.

MiMedx Group excels in Q2, eyes growth amid challenges

MiMedx Group's Q2 2023 performance reflects strong financial results, operational efficiency, and a strategic shift towards wound and surgical markets.
While facing challenges related to supply chain disruptions and regulatory compliance, the company is well-positioned to capitalize on growth opportunities and drive innovation.
Investors can be optimistic about MiMedx Group's financial outlook, legal standing, and commitment to market expansion through product development and strategic partnerships.

MiMedx Group reports robust Q3 earnings, eyes Japanese market growth

MiMedx Group's Q3 performance reflects strong financial results, strategic product launches, and growth in key markets despite challenges.
The company's focus on operational efficiency, expansion in the Japanese market, and product portfolio diversification position it well for future success.
While facing challenges from Medicare LCD changes and potential cannibalization, MiMedx remains optimistic about growth opportunities and aims for continued momentum.

MiMedx Group excels in Q4, poised for sustained growth

MiMedx Group's Q4 performance exceeded expectations with revenue growth and improved margins.
The company's strategic focus on growth drivers and financial discipline sets a strong foundation for 2024.
While facing challenges in certain areas, MiMedx is well-positioned to capitalize on opportunities for expansion.
Overall, MiMedx's financial health and growth prospects indicate a positive outlook for the future.

MiMedx Group reports robust Q1 earnings amidst strategic growth plans

MiMedx Group (MDXG) had a strong start in Q1 2024, showcasing financial strength and strategic focus on growth.
The company faces challenges from potential market disruptions and cost pressures but remains optimistic about opportunities.
Key initiatives include product innovation, market expansion, and navigating reimbursement landscape changes.

MiMedx Group reports solid Q2 earnings, navigates reimbursement challenges

MiMedx Group's Q2 performance reflects steady growth, strong financial health, and a strategic focus on innovation and customer relationships.
While facing challenges in reimbursement dynamics and regulatory uncertainties, the company remains resilient and poised for growth opportunities in the market.
With a solid product portfolio and emphasis on operational efficiency, MiMedx Group is well-positioned to navigate challenges and capitalize on future market prospects.

MiMedx Group reports solid Q3 growth amid reimbursement challenges

MiMedx Group's Q3 performance reflects resilience and growth amidst challenges, with a focus on innovation and customer-centric strategies for future success.
The company's financial stability, positive market reception of HELIOGEN, and increasing platform adoption position it well for capitalizing on opportunities ahead.
While facing challenges in reimbursement dynamics and operational efficiency, MiMedx Group remains optimistic about future corrections and growth prospects.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

August starts the watch for restatements of MiMedx's financials possibly right before the company's yet to be scheduled 2019 Annual Meeting.

MiMedx: Could Finish 2018 With A Bang While 2020 Could Be Even Better

The beleaguered company has made significant progress in the last two months to right the ship but the shorts continue to press with a thesis that has drifted substantially.

MiMedx Group: Hidden Asset In Osteoarthritis

MiMedx Group Is More Than Just A Restatement Play With An Enormous Hidden Asset In Osteo-Arthritis

MiMedx Group Is More Than Just A Restatement Play With An Enormous Hidden Asset In Osteoarthritis

Annual meeting on June 17th will be an inflection point for the company with former CEO Petit either embraced or shunned by MiMedx shareholders.

MiMedx: Upside Catalyst Is Right Around The Corner

Strong volume and sustained price action are a great signal for investors for very good reasons.

MiMedx: Why I'm Buying The Breakout

A new board could signify the start of a turnaround.

Here's Why Shares of MiMedx Group Jumped Higher Today

MiMedx Group Inc. said Thursday it would be overhauling its board of directors, a decision the company said it made in cooperation with one of its largest shareholders, Prescience Point Capital Management LLC.

MiMedx announces overhaul of board after exec spying scandal

MiMedx Group Inc can't seem to leave controversy behind. Even as the company announced the conclusion of an independent audit committee investigation into some of its business practices, a new report in the Wall Street Journal said the company's injectables are not meeting regulatory standards.

WSJ: MiMedx Injectables Flout FDA Regulations

News about the former CEO Pete Petit is not enough of a reason to justify the recent sell-off in MiMedx stock.

Institutional Investors Are Buying MiMedx Again As The Stock Has Had A Nice Recent Pullback

News for MiMedx Group Stock (MDXG)